Medline (NASDAQ:MDLN) Announces Quarterly Earnings Results

Medline (NASDAQ:MDLN) issued its earnings results on Wednesday. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.32 by $0.12, FiscalAI reports. The firm had revenue of $7.86 billion during the quarter.

Here are the key takeaways from Medline’s conference call:

• Positive Sentiment: Third-quarter net sales rose 10% to $7.9 billion, and Adjusted EBITDA increased 12% to $1.0 billion. Growth was broad-based, though EBITDA included an $81 million benefit from tariff refunds.
• Positive Sentiment: Medline raised its 2026 organic sales growth outlook for the third consecutive quarter, to 10%–10.5%, while reaffirming Adjusted EBITDA guidance of $3.3 billion–$3.4 billion, expected near the midpoint.
• Negative Sentiment: Management expects 2027 sales growth in the high single digits but EBITDA growth only in the low to mid-single digits, citing elevated inflation and investment in capacity, operations, and quality. It expects EBITDA growth to return to at least sales growth in 2028.
• Positive Sentiment: Medline reported strong customer signings and said it remains on track for its $1 billion 2026 goal; it is also expanding distribution capacity with four facilities planned or underway and progressing with its first Canadian Prime Vendor rollout.
• Negative Sentiment: The Global Quality Action Plan is a multi-year effort involving third-party assessments and ongoing investment and remediation. Medline is exiting its roughly $60 million home-care-bed business, and management acknowledged other issues could emerge as it assesses its network.

Medline Price Performance

NASDAQ MDLN traded down $0.86 during trading hours on Thursday, reaching $39.49. The company’s stock had a trading volume of 6,923,824 shares, compared to its average volume of 7,742,550. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.61 and a current ratio of 4.33. The company’s 50-day moving average is $34.58 and its two-hundred day moving average is $39.53. Medline has a fifty-two week low of $31.37 and a fifty-two week high of $50.88. The stock has a market cap of $51.92 billion and a PE ratio of 50.07.

Wall Street Analysts Forecast Growth

A number of research firms have commented on MDLN. Tigress Financial reduced their target price on Medline from $62.00 to $55.00 and set a “buy” rating for the company in a report on Tuesday, August 11th. Mizuho reduced their price objective on shares of Medline from $48.00 to $45.00 and set an “outperform” rating for the company in a research note on Thursday, October 22nd. Deutsche Bank Aktiengesellschaft set a $37.00 target price on shares of Medline and gave the stock a “hold” rating in a research report on Thursday, August 6th. William Blair reiterated an “outperform” rating on shares of Medline in a research report on Wednesday, September 23rd. Finally, BMO Capital Markets reissued an “outperform” rating and set a $47.00 price target on shares of Medline in a research note on Thursday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $46.54.

Key Headlines Impacting Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline earned $0.44 per share, above the $0.32 consensus, on revenue of $7.86 billion. Reports also highlighted improved full-year growth expectations, although the company reaffirmed its adjusted EBITDA outlook. Medline Q3 2026 earnings
• Positive Sentiment: The company plans to repurchase $1 billion of shares, which could support per-share results and signal confidence in its business. Q3 beat and share buybacks
• Positive Sentiment: BTIG reaffirmed its Buy rating and set a $55 price target, implying substantial upside from the cited share price. Barclays also issued a Buy rating, adding to favorable analyst sentiment. Barclays rating
• Neutral Sentiment: Medline plans 2027 price increases to offset inflation. The move may help protect margins, but its impact will depend on customers’ ability and willingness to absorb higher prices. Pricing plans and Q3 results
• Negative Sentiment: A law firm announced an investigation into potential securities-fraud claims related to alleged product-quality issues and prior stock declines. The announcement is not a finding of wrongdoing, but the matter could create legal and reputational risk. Securities investigation announcement

Insider Transactions at Medline

In other Medline news, major shareholder Private Ltd Gic sold 2,570,999 shares of the company’s stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $35.35, for a total value of $90,884,814.65. Following the sale, the insider owned 20,231,483 shares of the company’s stock, valued at $715,182,924.05. This represents a 11.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 8,538,960 shares of company stock worth $302,807,442 in the last ninety days. Insiders own 0.81% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of MDLN. Janus Henderson Group PLC boosted its position in shares of Medline by 8.4% in the first quarter. Janus Henderson Group PLC now owns 11,451,861 shares of the company’s stock worth $506,546,000 after acquiring an additional 887,240 shares during the last quarter. Banque Pictet & Cie SA boosted its holdings in Medline by 2.0% in the third quarter. Banque Pictet & Cie SA now owns 7,455,089 shares of the company’s stock valued at $258,692,000 after acquiring an additional 142,939 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund raised its holdings in shares of Medline by 233.3% in the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 5,000,000 shares of the company’s stock worth $222,500,000 after purchasing an additional 3,500,000 shares during the period. Bessemer Group Inc. raised its holdings in shares of Medline by 39,404.0% in the 1st quarter. Bessemer Group Inc. now owns 3,504,006 shares of the company’s stock worth $155,929,000 after purchasing an additional 3,495,136 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its holdings in Medline by 30,255.5% in the third quarter. Allspring Global Investments Holdings LLC now owns 2,700,425 shares of the company’s stock valued at $94,353,000 after buying an additional 2,691,529 shares during the period.

About Medline

Medline Industries, Inc is a medical-supply manufacturer and distributor headquartered in Northfield, Illinois. The company provides products and supply-chain services to healthcare organizations, including hospitals, ambulatory surgery centers, physician offices, long-term care facilities, home health providers and other care settings.

Its product portfolio includes medical-surgical supplies, surgical and operating-room products, patient-care items, examination gloves, protective apparel, laboratory products, respiratory-care equipment, durable medical equipment and products for infection prevention.